Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Recruitment Status: Not yet recruiting"
topic_facet:"Medical Condition: Human Immunodeficiency Virus (HIV-1) Infection MedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02]"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Not+yet+recruiting%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Human+Immunodeficiency+Virus+%28HIV-1%29+Infection+MedDRA+version%3A+20.1Level%3A+LLTClassification+code+10068341Term%3A+HIV-1+infectionSystem+Organ+Class%3A+100000004862%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Virus+Diseases+%5BC02%5D%22&lookfor=%22Virus+Diseases%22&type=Subject
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Not+yet+recruiting%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Human+Immunodeficiency+Virus+%28HIV-1%29+Infection+MedDRA+version%3A+20.1Level%3A+LLTClassification+code+10068341Term%3A+HIV-1+infectionSystem+Organ+Class%3A+100000004862%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Virus+Diseases+%5BC02%5D%22&lookfor=%22Virus+Diseases%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Not+yet+recruiting%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Human+Immunodeficiency+Virus+%28HIV-1%29+Infection+MedDRA+version%3A+20.1Level%3A+LLTClassification+code+10068341Term%3A+HIV-1+infectionSystem+Organ+Class%3A+100000004862%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Virus+Diseases+%5BC02%5D%22&lookfor=%22Virus+Diseases%22&type=Subject
PubPharm (38)
1
A study to test the safety, tolerability and ability to maintain HIV suppression of switching from a tenofovir disoproxil fumarate (TDF) containing regimen to elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) in the HIV-1 infected subjects aged = 60 years who are virologically suppressed. : A Phase 3b, Randomized, Open-Label Study to Evaluate Switching from a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Subjects Aged = 60 Years - -
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
2
A study to test the safety, tolerability and ability to maintain HIV suppression of switching from a tenofovir disoproxil fumarate (TDF) containing regimen to elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) in the HIV-1 infected subjects aged = 60 years who are virologically suppressed. : A Phase 3b, Randomized, Open-Label Study to Evaluate Switching from a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Subjects Aged = 60 Years - -
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
3
A study to test the safety, tolerability and ability to maintain HIVsuppression of of switching from a current regimen consisting ofabacavir/lamivudine (ABC/3TC) plus a third antiretroviral agent to theelvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF)fixed-dose combination (FDC) in the HIV-1 infected subjects who arevirologically suppressed. : A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety andEfficacy of Switching from Regimens Consisting of Abacavir/Lamivudine(ABC/3TC) plus a Third Antiretroviral Agent to theElvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-1 InfectedAdult Subjects - NA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
4
A study to test the safety, tolerability and ability to maintain HIVsuppression of of switching from a current regimen consisting ofabacavir/lamivudine (ABC/3TC) plus a third antiretroviral agent to theelvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF)fixed-dose combination (FDC) in the HIV-1 infected subjects who arevirologically suppressed. : A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety andEfficacy of Switching from Regimens Consisting of Abacavir/Lamivudine(ABC/3TC) plus a Third Antiretroviral Agent to theElvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-1 InfectedAdult Subjects - NA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
5
This study will test an experimental drug called GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) fixed dose combination (FDC) for the treatment of HIV-1 infection. The purpose of this study is to test safety and to test whether GS-9883/F/TAF as a FDC works as well as the FDC drug containing abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) (trade name Triumeq). The study will also test whether GS-9883/F/TAF maintains the control of HIV-1 infection effectively compared to ABC/DTG/3TC. : A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
6
This study will test an experimental drug called GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) for the treatment of HIV-1 infection. The purpose of this study is to evaluate safety, and to determine whether GS-9883/F/TAF as a fixed dose combination maintains the control of HIV-1 infection effectively compared to treatment with dolutegravir (DTG) (trade name Tivicay) and emtricitabine/tenofovir alafenamide (F/TAF). : A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
7
This study will test an experimental drug called GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) fixed dose combination (FDC) for the treatment of HIV-1 infection. The purpose of this study is to test safety and to test whether GS-9883/F/TAF as a FDC works as well as the FDC drug containing abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) (trade name Triumeq). The study will also test whether GS-9883/F/TAF maintains the control of HIV-1 infection effectively compared to ABC/DTG/3TC. : A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
8
This study will test an experimental drug called GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) for the treatment of HIV-1 infection. The purpose of this study is to evaluate safety, and to determine whether GS-9883/F/TAF as a fixed dose combination maintains the control of HIV-1 infection effectively compared to treatment with dolutegravir (DTG) (trade name Tivicay) and emtricitabine/tenofovir alafenamide (F/TAF). : A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
9
This study will test an experimental drug called GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) fixed dose combination (FDC) for the treatment of HIV-1 infection. The purpose of this study is to test safety and to test whether GS-9883/F/TAF as a FDC works as well as the FDC drug containing abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) (trade name Triumeq). The study will also test whether GS-9883/F/TAF maintains the control of HIV-1 infection effectively compared to ABC/DTG/3TC. : A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Na¿ve Adults - This study will test an experimental drug called GS-9883/emtricitabine/tenofovir alafenamide (GS-988
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
10
This study will test an experimental drug called GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) fixed dose combination (FDC) for the treatment of HIV-1 infection. The purpose of this study is to test safety and to test whether GS-9883/F/TAF as a FDC works as well as the FDC drug containing abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) (trade name Triumeq). The study will also test whether GS-9883/F/TAF maintains the control of HIV-1 infection effectively compared to ABC/DTG/3TC. : A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Na¿ve Adults - This study will test an experimental drug called GS-9883/emtricitabine/tenofovir alafenamide (GS-988
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
1
2
3
4
Nächster »
[4]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: Recruitment Status: Not yet recruiting
Filter aufheben
Thema: Medical Condition: Human Immunodeficiency Virus (HIV-1) Infection MedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02]
Medienart
38
Aufsätze
38
E-Artikel
38
E-Ressourcen
Zeitschriftentitel
38
WHO International Clinical Trials Registry Plat...
Thema
38
610
Medical Condition: Human Immunodeficiency Virus...
38
Phase: Phase 3
Recruitment Status: Not yet recruiting
38
Study Type: Interventional
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
36
2020-
2
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
38
Englisch
Haven't found what you're looking for?
Wird geladen...